全文获取类型
收费全文 | 1803篇 |
免费 | 127篇 |
国内免费 | 9篇 |
专业分类
耳鼻咽喉 | 23篇 |
儿科学 | 98篇 |
妇产科学 | 13篇 |
基础医学 | 184篇 |
口腔科学 | 40篇 |
临床医学 | 208篇 |
内科学 | 311篇 |
皮肤病学 | 31篇 |
神经病学 | 97篇 |
特种医学 | 110篇 |
外科学 | 295篇 |
综合类 | 17篇 |
预防医学 | 169篇 |
眼科学 | 85篇 |
药学 | 118篇 |
中国医学 | 4篇 |
肿瘤学 | 136篇 |
出版年
2023年 | 18篇 |
2022年 | 30篇 |
2021年 | 76篇 |
2020年 | 40篇 |
2019年 | 49篇 |
2018年 | 49篇 |
2017年 | 42篇 |
2016年 | 42篇 |
2015年 | 49篇 |
2014年 | 68篇 |
2013年 | 74篇 |
2012年 | 75篇 |
2011年 | 68篇 |
2010年 | 57篇 |
2009年 | 41篇 |
2008年 | 42篇 |
2007年 | 49篇 |
2006年 | 52篇 |
2005年 | 54篇 |
2004年 | 44篇 |
2003年 | 43篇 |
2002年 | 47篇 |
2001年 | 40篇 |
2000年 | 32篇 |
1999年 | 34篇 |
1998年 | 28篇 |
1997年 | 30篇 |
1996年 | 34篇 |
1995年 | 24篇 |
1994年 | 30篇 |
1993年 | 20篇 |
1992年 | 35篇 |
1991年 | 39篇 |
1990年 | 37篇 |
1989年 | 34篇 |
1988年 | 42篇 |
1987年 | 39篇 |
1986年 | 33篇 |
1985年 | 31篇 |
1984年 | 19篇 |
1983年 | 22篇 |
1980年 | 14篇 |
1979年 | 18篇 |
1977年 | 14篇 |
1976年 | 15篇 |
1975年 | 12篇 |
1974年 | 15篇 |
1972年 | 16篇 |
1969年 | 9篇 |
1968年 | 12篇 |
排序方式: 共有1939条查询结果,搜索用时 15 毫秒
1.
A. A. Vo M. Toyoda A. Peng S. Bunnapradist M. Lukovsky S. C. Jordan 《American journal of transplantation》2006,6(10):2384-2390
Here we retrospectively examine the efficacy of two antibody induction regimens using Zenapax or Thymoglobulin in patients with positive complement-dependent cytotoxicity crossmatches (CDC-CMXs) desensitized with IVIG (intravenous immunoglobulin). Between January 1999 and March 2005, 97 patients with (+) CDC-CMXs received kidney transplants (43 deceased donors/54 living donors). All patients received at least 2 g/kg IVIG (maximum four doses) until an acceptable CMX was obtained. Patients were divided into two groups: 1. IVIG + Zenapax (n = 58), 2. IVIG + Thymoglobulin (n = 39). A total of 94% of patients in Group 1 and 84% in G2 have at least 2 years of follow up. Patient and graft survival was 96%/84% in Group 1 and 100%/90% in Group 2, p = NS. The number and severity of AR episodes were similar (36% Group 1 vs. 31% Group 2, p = NS) as was the incidence of C4d (+) antibody-mediated rejection (AMR) (Banff Grade II/III) (22% Group 1 vs. 21% Group 2). Mean serum creatinines (SCrs) at 24 months were similar (Group 1: 1.4 +/- 0.7 vs. G2: 1.5 +/- 0.7 mg/dL). Induction therapy with Zenapax or Thymoglobulin results in excellent patient, graft survival and graft function at 2 years. There was no increased risk of viral infections or malignancies with either agent. Neither agent was effective in reducing the incidence of AMR. 相似文献
2.
3.
4.
Benign intracranial hypertension and recombinant growth hormone therapy in Australia and New Zealand
PA Crock JD McKenzie AM Nicoll NJ Howard W Cutfield LK Shield G Byrne 《Acta paediatrica (Oslo, Norway : 1992)》1998,87(4):381-386
Benign intracranial hypertension (BIH) is reported in three children from Australia and one from New Zealand, who were being treated with recombinant human growth hormone (rhGH). Three males and one female, aged between 10.5 and 14.2 y, developed intracranial hypertension within 2 weeks to 3 months of starting treatment. A national database, OZGROW, has been prospectively collecting data on all 3332 children treated with rhGH in Australia and New Zealand from January 1986 to 1996. The incidence of BIH in children treated with growth hormone (GH) is small, 1.2 per 1000 cases overall, but appears to be greater with biochemical GHD (<10IUml -1 ), i.e. 6.5/1000 (3 in 465 cases), relative risk 18.4, 95% confidence interval 1.9-176.1, than in all other children on the database. The incidence in patients with Turner's syndrome was 2.3/1000 (1 in 428 cases). No cases in patients with partial GHD (10–20 IUml -1 ) or chronic renal failure were identified. Possible causative mechanisms are discussed. The authors'practice is now to start GH replacement at less than the usual recommended dose of 14IUm-2 week-1 in those children considered to be at high risk of developing BIH. Ophthalmological evaluation is recommended for children before and during the first few months following commencement of rhGH therapy and is mandatory in the event of peripheral or facial oedema, persistent headaches, vomiting or visual symptoms. The absence of papilledema does not exclude the diagnosis. 相似文献
5.
6.
M J Coppes M F Tournade J Lemerle S Weitzman A Rey D Burger M Carli P A Vo?te 《Cancer》1992,69(11):2721-2725
The International Society of Pediatric Oncology (SIOP) recommends preoperative treatment in the management of eligible patients with Wilms' tumor. Until 1980, children younger than 12 months of age (infants) at diagnosis had been excluded from the SIOP trials. SIOP 6, conducted from 1980 to 1987, was the first SIOP study to include infants older than 6 months of age. This retrospective analysis of 145 infants registered to SIOP 6 demonstrates that in infants older than 6 months and having favorable histology (FH), a two-drug preoperative chemotherapy (CT) regimen of 4 weeks significantly ameliorated stage distribution as determined at delayed surgery but did not affect a good outcome. However, the CT dose utilized in SIOP 6 resulted in an unacceptable toxicity in this age group, and SIOP 9, the new SIOP study of Wilms' tumor, recommends a reduced dose of CT in infants. Preoperative CT is not recommended in infants younger than 6 months of age. Specifically, the high incidence (29%) of mesoblastic nephroma in this age group does not justify such an approach. Histopathologic diagnosis should be obtained in these patients before any treatment. 相似文献
7.
8.
Intravenous Gammaglobulin (IVIG): A Novel Approach to Improve Transplant Rates and Outcomes in Highly HLA-Sensitized Patients 总被引:2,自引:0,他引:2
S. C. Jordan A. A. Vo A. Peng M. Toyoda D. Tyan 《American journal of transplantation》2006,6(3):459-466
Intravenous immunoglobulin (IVIG) products are derived from pooled human plasma and have been used for the treatment of primary immunodeficiency disorders for more than 24 years. Shortly after their introduction, IVIG products were also found to be effective in the treatment of autoimmune and inflammatory disorders. Over the past 2 decades, the list of diseases where IVIG has a demonstrable beneficial effect has grown rapidly. These include Kawasaki disease, Guillain-Barre syndrome, myasthenia gravis, dermatomyositis and demyelinating polyneuropathy. Recently, we have described a beneficial effect on the reduction of anti-HLA antibodies with subsequent improvement in transplantation of highly HLA-sensitized patients as well as a potent anti-inflammatory effect that is beneficial in the treatment of antibody-mediated rejection (AMR). These advancements have enabled transplantation of patients previously considered untransplantable. These studies and relevant mechanism(s) of action will be discussed here. 相似文献
9.
10.
A A Timofeev V A Znamenski? T G Vo?tsekhovskaia A I Gorban' N V Bogdan N A Kravets 《Klinichna khirurhiia / Ministerstvo okhorony zdorov'ia Ukra?ny, Naukove tovarystvo khirurhiv Ukra?ny》1990,(1):37-38
The use for local treatment in 45 patients with abscesses and phlegmons of lysozyme immobilized in polymethylsiloxane contributed to acceleration in wound cleaning of necrotic masses, active granulation and epithelization, reduction in duration of patients' treatment by 3-5 days. 相似文献